362703-34-2

Basic information

• Product Name: 1-tert-butyl4-Methyl4-cyanopiperidine-1,4-dicarboxylate
• Synonyms: 1-tert-butyl4-Methyl4-cyanopiperidine-1,4-dicarboxylate;Methyl 4-cyanopiperidine-4-carboxylate hydrochloride;1,4-Piperidinedicarboxylic acid, 4-cyano-, 1-(1,1-dimethylethyl) 4-methyl ester
• CAS NO: 362703-34-2
• Molecular Formula: C₁₃H₂₀N₂O₄
• Molecular Weight: 269.31684
• Mol File: 362703-34-2.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-tert-butyl4-Methyl4-cyanopiperidine-1,4-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-tert-butyl4-Methyl4-cyanopiperidine-1,4-dicarboxylate(362703-34-2)
• EPA Substance Registry System: 1-tert-butyl4-Methyl4-cyanopiperidine-1,4-dicarboxylate(362703-34-2)

Safety Data

• Hazardous Substances Data: 362703-34-2(Hazardous Substances Data)

Usage

General Description

1-tert-butyl-4-methyl-4-cyanopiperidine-1,4-dicarboxylate is a chemical compound that belongs to the piperidine class of organic compounds. It is a derivative of piperidine, which is commonly used in the synthesis of pharmaceutical drugs. This specific compound is also known as Boc-4-Cyano-L-Proline a-methyl ester, and it is used as a building block in the synthesis of various pharmaceutical and medicinal products. It has a tert-butyl and a methyl group attached to the piperidine ring, as well as a cyano group and two carboxylate groups, which give it its unique properties and potential applications in drug development and research.

Upstream product

• 362703-33-1 C₁₆H₁₈N₂O₄ 
• 24424-99-5 di-tert-butyl dicarbonate 
• 105-34-0 methyl 2-cyanoacetate 
• 159635-50-4 Bis-(2-bromo-ethyl)-carbamic acid tert-butyl ester 
• 91419-52-2 1-tert-butoxycarbonyl-4-cyanopiperidine 
• 1016258-66-4 1-(tert-butyl) 4-ethyl 4-cyanopiperidine-1,4-dicarboxylate 
• 124-41-4 sodium methylate 
• 4395-98-6 4-cyanopiperidine 

Downstream Products

• 1338251-67-4 C₁₇H₂₄N₂O₅*ClH 
• 1338251-68-5 C₁₅H₁₈Cl₂N₂O₃*ClH 
• 1338251-86-7 C₂₅H₃₂N₂O₆ 
• 1338251-87-8 C₂₅H₃₂N₂O₆ 
• 1338251-88-9 C₂₅H₃₂N₂O₆ 
• 1338251-89-0 C₂₅H₂₉F₃N₂O₅ 
• 1338251-90-3 C₂₅H₂₉F₃N₂O₅ 
• 1338251-91-4 C₂₅H₂₉F₃N₂O₅ 
• 1338251-92-5 C₂₉H₃₆N₂O₆ 
• 1338251-93-6 C₂₅H₃₂N₂O₅ 
• 1338251-94-7 C₂₃H₂₆Cl₂N₂O₄ 
• 1338251-95-8 C₂₃H₂₆Cl₂N₂O₄ 
• 1338251-96-9 C₂₃H₂₆Cl₂N₂O₄ 
• 1338251-97-0 C₂₃H₂₃Cl₂F₃N₂O₃ 

Relevant articles and documents

LIM KINASE INHIBITORS

The present invention relates to new kinase inhibitors, more specifically LIM Kinase inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and Prophylaxis of disease. In particular, the present invention relates to new LIMK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and Prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said Compounds in the manufacture of a medicament for the application to a number of therapeutic indications including Ophthalmic and intestinal diseases.

Synthesis and structure-activity relationship of a novel, achiral series of TNF-α converting enzyme inhibitors

A novel series of achiral TNF-α converting enzyme (TACE) inhibitors has been discovered. These compounds exhibited activities from 0.35 to 11 nM in a porcine TACE assay and inhibited TNF-α production in an LPS-stimulated whole blood assay with an IC5